Cadila Health up 3% on product launch & USFDA nod to skin drug

Moneycontrol News Cadila Healthcare soared nearly 3 percent intraday on Monday, driven by a product launch as well as US drug regulator’s nod to skin infection medication. Cadila’s subsidiary, Zydus Cadila, received regulatory approvals to launch tetravalent inactivated influenza vaccine for seasonal flu in India. The company received regulatory nods from Drug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) and Central Drug Laboratory (CDL) to market the tetravalent inactivated influenza vaccine Vaxiflu 4 for seasonal flu, Cadila Healthcare said in a filing to BSE. "The vaccine provides protection from four influenza viruses -- H1N1, H3N2, Type B (Brisbane) and Type B (Phuket)," it added.Zydus also received the approval from US Food and Drug Administration (FDA) for Linezolid tablets. These are used to treat skin infections and pneumonia. The stock gained over 16 percent in the past 15 days. At 10:31 hrs, it was quoting at Rs 434.70, up Rs 4.65, or 1.08 percent on the BSE. It touched an intraday high of Rs 442.00 and an intraday low of Rs 433.90.